Athira Pharma
Bothell, Washington, United States · Biotechnology, Health Care, Pharmaceutical · 135 employees
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration.
Funding history
- Funding Round — $90.0M — Dec 2025
- Funding Round — $89.0M — Jun 2020
- Funding Round — $3.8M — Jan 2020
- Series seed — $1.3M — Dec 2018
- Funding Round — $14.1M — Nov 2017
Recent signals
- Feb 03, 2026: LeonaBio Appoints Mark F. Kubik as Chief Business Officer
- Dec 18, 2025: Raised $90.0M
- Nov 06, 2025: SEC 8-K (2.01): On November 6, 2025, Athira Pharma, Inc. announced its financial results for the quarter ended September 30, 2025. This filing represents the completion of the financial reporting process for the quarter, which highlights the company's operational performance and financial condition. The press release may contain important insights into revenue, expenses, and net income that influence investor perception and stock performance. Given the timing of this report, it reflects recent strategic developments and management's analysis of the company's performance over the last quarter.
- Apr 15, 2024: Athira Pharma Appoints Javier San Martin as Chief Medical Officer
- Jun 12, 2020: Raised $89.0M
- Jan 24, 2020: Raised $3.8M
- Dec 20, 2018: Raised $1.3M in Series seed
- Nov 01, 2017: Raised $14.1M
See plans & pricing → Track Athira Pharma’s funding, hiring, and signals — with verified contacts — on Fundz.